The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) activities for physicians.
CREDIT DESIGNATION STATEMENT
The AACR has designated this live activity for a maximum of 45.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
CLAIMING CME CREDIT
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this continuing medical education activity must complete the CME Request for Credit Survey by Wednesday, May 21. Certificates will only be issued to those who complete the survey. Information about CME-accredited sessions and how to access the Request for Credit Survey will be available at the AACR CME Booth in the registration area in the San Diego Convention Center.
STATEMENT OF EDUCATIONAL NEED, TARGET AUDIENCE, AND LEARNING OBJECTIVES
New technologies, scientific advances, and exponential developments in the field of translational cancer medicine have led to changes in oncology practice and significant patient benefit. By bridging the gap between what physicians understand about cancer biology and the clinical applications, this meeting aids basic researchers, physicians, and clinician-scientists in obtaining, synthesizing, and integrating the most cutting-edge research. This exposure is essential for the implementation of best practices, such as the most current molecular-based tests to aid in the diagnosis, treatment, and prevention of cancer. Through the active participation of clinical investigators and physicians in the meeting, laboratory researchers will obtain a better understanding of the wider context of their research in the “bench-to-bedside” continuum.
After participating in this CME activity, physicians should be able to:
- Identify technological advances and tools to accelerate progress in cancer research, improve early detection, and early intervention, with the ultimate goal of extending patients’ lives and improving their quality of life.
- Explain the integration of information from basic and translational sciences to drug development, clinical research, and application of new findings.
- Integrate the use of biomarkers and other indicators to improve patient selection (or stratification) for clinical trials.
- Incorporate the latest research findings regarding therapies and treatment options in a variety of cancer types in order to improve patient outcomes.
- Formulate new strategies that will further scientific and clinical research efforts toward the prevention and early detection of cancer.
- Develop collaborations among physicians, researchers, and clinician-scientists to advance the cause of treating and preventing cancer
It is the policy of the AACR that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR will provide information that Program Committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Annual Meeting Program Supplement.
ACKNOWLEDGEMENT OF FINANCIAL OR OTHER SUPPORT
This activity is supported by the following professional education grants: AbbVie, Celgene, Eisai, Jazz Pharmaceuticals, Lilly, Millennium, Seattle Genetics, and Pfizer. Any others will be disclosed at the meeting.
QUESTIONS ABOUT CME?
Please contact the Office of CME at 215-440-9300 or firstname.lastname@example.org.
AACR Annual Meeting 2014 • April 5-9, 2014 • San Diego Convention Center • San Diego, California